Demant A/S: Restated comparative figures for 2023
|
Investor news |
1 August 2024 |
Restated comparative figures for 2023
On 5 February 2024, Demant announced the decision to undertake a strategic review of its Communications business segment. In accordance with IFRS 5 – Non-current Assets Held for Sale and Discontinued Operations and as previously communicated, Communications is therefore recognised in the Group’s financial reporting as a discontinued operation together with Hearing Implants, and comparative figures for 2023 are restated to reflect this. To help reconcile these figures, we attach restated income statements and statement of free cash flow before acquisitions (unaudited) for continuing operations for the following reporting periods: H1 2023, H2 2023 and FY 2023.
|
Further information: Søren Nielsen, President & CEO Phone +45 3917 7300 |
Other contacts: René Schneider, CFO Peter Pudselykke, Head of Investor Relations Henrik Axel Lynge Buchter, Manager of External Communications |
Contacts
Henrik Axel Lynge Buchter
External Communication Manager
Corporate Communication & Sustainability
Tel:
About Demant A/S
Demant is a world-leading hearing healthcare group that offers solutions and services to help people with hearing loss connect with the world around them. In every aspect, from hearing devices, hearing implants, diagnostics to audio and video solutions and hearing care all over the world, Demant is active and engaged. Our innovative technologies and know-how help improve people’s health and hear-ing. We create life-changing differences through hearing health.
Alternative languages
Attachments
Subscribe to our company announcements
Keep up to date with our company announcements by subscribing.
Visit our pressroom and see more company announcements from us.
Our pressroom